Capricor Therapeutics (STU:4LN2) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:4LN2 Capricor Therapeutics Inc STU:4LN2
35 GF Score
Price €3.32
GF Value €4.12
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Capricor Therapeutics FFO per Share?

FFO per Share only applies to REITs.

STU:4LN2
35GF Score
Capricor Therapeutics Inc STU:4LN2
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Capricor Therapeutics (STU:4LN2) Overvalued in 2026?

Based on GuruFocus' analysis, Capricor Therapeutics stock appears to be undervalued. The current stock price of €3.32 is trading 19.3% below its estimated GF Value™ of €4.12. GuruFocus considers Capricor Therapeutics to be Modestly Undervalued.

Key valuation signals for STU:4LN2:

  • FFO per Share:
  • GF Value™: €4.12 vs. price of €3.32 (19.3% below fair value)
  • GF Score™: 35/100 with 3 warning signs

No single metric tells the full story. See the STU:4LN2 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Capricor Therapeutics Business Description

Other Exchanges CAPR:USA
Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
35GF Score

Get the complete analysis for STU:4LN2

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.32
Price
€4.12
GF Value